KRAS and neoplasm: Furthermore, we observed an upregulation of FAK in specific tumor types with gene mutations or aberrant protein expression, such as BRAF/KRAS mutations, CDH1 deletions, EGFR or HER2 overexpression, and mediated drug resistance processes (Tong et al., 2019; Yuen et al., 2021; Yu et al., 2022; Castro-Guijarro et al., 2023).